MedElevator
Войти в исследования Journal of medical case reports · 2025
Evaluating the technetium-99 m pertechnetate flow protocol for Graves' disease: methodological insights: a case series.
СтатьяКлинический случайНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Asiri Jaber Abdulwahab, Alghamdi Rami Abdullah, AlRizqi Ahmed Ali, Alrasheed Shahad Khalaf, Alaythan Abdulaziz, Alshammri Bander Mukhlef, Alshehri Mohammed Abdullah, Alarjani Mohammed Hadi, Alshehri Zyad, ALFawaz Nahed Nasser, Albalawi Rayan Saad
Аннотация
BACKGROUND: Graves' disease is the most prevalent cause of hyperthyroidism globally, with technetium-99m pertechnetate widely utilized in its diagnosis. Dynamic scintigraphy using technetium-99m pertechnetate has shown promise for early detection of Graves' disease, particularly in subclinical presentations, but lacks standardized evaluation. This study aims to explore the utility of a dynamic technetium-99m pertechnetate scintigraphy protocol in hyperthyroidism, focusing on its diagnostic advantages and potential clinical applications.
CASE PRESENTATION: The cases described involved adult male and female patients aged 34-40 years of Saudi Middle Eastern ethnicity.
CONCLUSIONS: Dynamic flow imaging using technetium-99m pertechnetate represents a promising diagnostic approach for Graves' disease, particularly in challenging subclinical cases. This protocol has the potential to refine diagnostic accuracy and guide treatment decisions. Further validation through larger studies is warranted to establish its clinical utility.
CASE PRESENTATION: The cases described involved adult male and female patients aged 34-40 years of Saudi Middle Eastern ethnicity.
CONCLUSIONS: Dynamic flow imaging using technetium-99m pertechnetate represents a promising diagnostic approach for Graves' disease, particularly in challenging subclinical cases. This protocol has the potential to refine diagnostic accuracy and guide treatment decisions. Further validation through larger studies is warranted to establish its clinical utility.